ES2150020T3 - Aumento de la concentracion de creatina y glucogeno en el musculo. - Google Patents

Aumento de la concentracion de creatina y glucogeno en el musculo.

Info

Publication number
ES2150020T3
ES2150020T3 ES95940388T ES95940388T ES2150020T3 ES 2150020 T3 ES2150020 T3 ES 2150020T3 ES 95940388 T ES95940388 T ES 95940388T ES 95940388 T ES95940388 T ES 95940388T ES 2150020 T3 ES2150020 T3 ES 2150020T3
Authority
ES
Spain
Prior art keywords
creatine
amount
muscle
increase
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940388T
Other languages
English (en)
Inventor
Paul Leonard Greenhaff
Allison Lesley Green
Ian Andrew Macdonald
Eric Hultman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9425514.8A external-priority patent/GB9425514D0/en
Application filed by University of Nottingham filed Critical University of Nottingham
Application granted granted Critical
Publication of ES2150020T3 publication Critical patent/ES2150020T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

METODOS Y COMPUESTOS PARA AUMENTAR LA RETENCION DE CREATINA Y LA CONCENTRACION DE GLUCOGENO EN EL MUSCULO DE SERES HUMANOS Y ANIMALES, INCLUYENDO EL AUMENTO DE LA CONCENTRACION DE CREATINA EN EL PLASMA DE UN ORGANISMO Y UN AUMENTO SUSTANCIALMENTE SIMULTANEO DE LA CONCENTRACION DE INSULINA PLASMATICA. LOS COMPUESTOS QUE INCLUYEN CREATINA O UN DERIVADO ACTIVO DE LA MISMA SE INTRODUCEN EN EL ORGANISMO POR INGESTION ORAL O INFUSION, POR EJEMPLO MEDIANTE INYECCION JUNTO A UN HIDRATO DE CARBONO, POR EJEMPLO GLUCOSA, PARA AUMENTAR LA LIBERACION DE INSULINA EN LA SANGRE QUE A SU VEZ INTRODUCE GLUCOSA EN EL MUSCULO PARA LA SINTESIS DE GLUCOGENO. EN EL COMPUESTO SE PUEDE INCLUIR INSULINA O UN DERIVADO ACTIVO DE LA MISMA JUNTO A O EN LUGAR DEL HIDRATO DE CARBONO.
ES95940388T 1994-12-17 1995-12-15 Aumento de la concentracion de creatina y glucogeno en el musculo. Expired - Lifetime ES2150020T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425514.8A GB9425514D0 (en) 1994-12-17 1994-12-17 Retention of creatine in the body
GBGB9517443.9A GB9517443D0 (en) 1994-12-17 1995-08-25 Increasing creatine and glycogen concentration in muscle

Publications (1)

Publication Number Publication Date
ES2150020T3 true ES2150020T3 (es) 2000-11-16

Family

ID=26306194

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940388T Expired - Lifetime ES2150020T3 (es) 1994-12-17 1995-12-15 Aumento de la concentracion de creatina y glucogeno en el musculo.

Country Status (11)

Country Link
US (1) US5968900A (es)
EP (1) EP0798971B1 (es)
AT (1) ATE194462T1 (es)
AU (1) AU4185696A (es)
CA (1) CA2208047C (es)
DE (1) DE69518008T2 (es)
DK (1) DK0798971T3 (es)
ES (1) ES2150020T3 (es)
GB (1) GB9517443D0 (es)
PT (1) PT798971E (es)
WO (1) WO1996018313A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7150880B2 (en) * 1996-05-31 2006-12-19 The Original Creatine Patent Co. Ltd. Compositions containing creatine and creatinine and a methyl xanthine
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) * 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6429198B1 (en) 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US20020119933A1 (en) 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6534480B2 (en) 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
GB9924650D0 (en) 1999-10-19 1999-12-22 Marathade Ltd Energy bar
US6703370B1 (en) 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
AU1800801A (en) * 1999-11-17 2001-05-30 Eric H. Kuhrts Exercise and muscle enhancement formulations
US6399661B1 (en) 2000-06-26 2002-06-04 Jeffrey M. Golini Oral creatine supplement and method for making same
US20030212134A1 (en) * 2001-04-16 2003-11-13 Dykstra John C. Combination of pinitol and creatine to enhance uptake and retention of creatine
US20030013767A1 (en) * 2001-07-13 2003-01-16 Samuel Bessman Method of treating weight loss using creatine
US20040052852A1 (en) * 2001-09-25 2004-03-18 Michael Farber Carbohydrate-based delivery system for creatine and other bioactive ingredients
US7067150B2 (en) * 2002-04-16 2006-06-27 Scepter Holdings, Inc. Delivery systems for functional ingredients
AU2003234146A1 (en) * 2002-04-22 2003-11-03 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
WO2004069236A1 (ja) 2003-02-06 2004-08-19 Otsuka Pharmaceutical Factory, Inc. 周術期血糖値上昇抑制剤
US7504118B2 (en) * 2003-04-11 2009-03-17 Fhg Corporation Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
WO2005110448A2 (en) * 2004-05-07 2005-11-24 Thermo Formulations Ltd. Nutritional composition for increasing creatine uptake in skeletal muscle
US20060045906A1 (en) * 2004-08-25 2006-03-02 Gardiner Paul T Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
US8613959B2 (en) * 2009-02-10 2013-12-24 Fhg Corporation Dietary supplements containing extracts of Nelumbo and processes of using same
US8703719B1 (en) 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
EP3411041A1 (en) 2016-02-01 2018-12-12 RiboCor, Inc. Use of ribose for treatment of subjects having congestive heart failure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1240336B (it) * 1990-03-21 1993-12-07 Setra Composizioni farmaceutiche,dietetiche o veterinarie ad attivita' eumetabolica
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot

Also Published As

Publication number Publication date
CA2208047A1 (en) 1996-06-20
US5968900A (en) 1999-10-19
AU4185696A (en) 1996-07-03
GB9517443D0 (en) 1995-10-25
DK0798971T3 (da) 2000-11-13
DE69518008T2 (de) 2001-05-17
CA2208047C (en) 2003-07-15
ATE194462T1 (de) 2000-07-15
MX9704388A (es) 1998-07-31
PT798971E (pt) 2000-12-29
EP0798971B1 (en) 2000-07-12
EP0798971A1 (en) 1997-10-08
WO1996018313A1 (en) 1996-06-20
DE69518008D1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
ES2150020T3 (es) Aumento de la concentracion de creatina y glucogeno en el musculo.
US6645948B2 (en) Nutritional composition for the treatment of connective tissue
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
Mok et al. Structured medium-chain and long-chain triglyceride emulsions are superior to physical mixtures in sparing body protein in the burned rat
Vinnars et al. History of parenteral nutrition
Gonce et al. Arginine supplementation and its effect on established peritonitis in guinea pigs
JPH04352718A (ja) 動物の肝臓のグリコーゲン貯蔵能力増大用治療剤
RU2001110097A (ru) Терапевтические композиции (ii)
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
KR920000324A (ko) 필수 지방산 처리법
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR880005933A (ko) 비타민 b6-함유 약제학적 제제
JPH01287041A (ja) 徐放性製剤
Waymack et al. Nutritional support of the burned patient
FI932740A0 (fi) Dryck foer intag foere operation
KR20140108170A (ko) 필러의 효능 유지용 조성물
León et al. Arginine supplementation improves histone and acute‐phase protein synthesis during gram‐negative sepsis in the rat
HK1068824A1 (en) Insulin for use in a dosage regime
KR920702225A (ko) 약학 조성물
EP0459377B1 (en) Use of E1 prostaglandin to cure male erectile inpotence
JPS57126420A (en) Drug for digestive organ
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
JPS6360940A (ja) 白内障の予防または治療剤
US4994492A (en) Treatment of melanoma using N,N-dimethylglycine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 798971

Country of ref document: ES